Webinar: 38 CAR T in Lymphoma: When the immune system needs assistance – cytopenias and infections in focus Join Prof. Mats Jerkeman (Skåne University Hospital, Lund, Sweden) and Prof. Per‑Ola Andersson (Sahlgrenska University Hospital, Gothenburg, Sweden) for an in‑depth lecture on immunological challenges following CAR T‑cell therapy in lymphoma. Webinar: 55 minutes When a CAR hits the blood – what happens next matters Post CAR T hematologic toxicity can shape recovery and outcomes. Join leading expert Dr. Kai Rejeski for concise, evidence based insights into ICAHT, prolonged cytopenias, and practical tools such as the CAR HEMATOTOX score to support post CAR T management. Webinar: 55 minutes Optimizing CAR-T Bridging Therapy in LBCL Listen in to Prof Thorsten Zenz, University Hospital Zürich in Switzerland, providing clinical experiences on timing and bridging therapies before CAR T-cell infusion in aggressive B-cell lymphoma, to gain new insights on how to optimize efficacy and safety of CAR-T in everyday practice. Interview: 2 minutes Post-CAR-T treatment and outpatient setting Listen in to insights on potential management of outpatient care and follow-up of CAR-T treatment in R/R LBCL by Mats Hellström, MD PhD, oncologist, adjunct associate professor at Uppsala University. Reading time ca 8 min Utbildning stärker personalens kompetens inom CAR-T-terapi För att ge trygg och säker vård vid CAR-T-behandling har en särskild körkortsutbildning införts. Här berättar Emma, sjuksköterska och CAR-T-koordinator på Sahlgrenska universitetssjukhuset i Göteborg, om varför den infördes och vilken nytta den gör. Se en kort videosummering (cirka 1:45 min) eller läs intervjun i sin helhet nedan. Duration: cirka 5 min Iceland to Lund - a collaboration in practice Listen to Robert Palmasson, hematologist at Skåne University Hospital in Lund Sweden, who shares the background and practical routines of the partnership on patients with LBCL and CAR-T treatment, between Iceland and Lund. Duration: 45 min Nytt nationellt vårdprogram aggressivt B-cellslymfom – fokus på CAR-T Se webbinarium om nytt svenskt, nationellt, vårdprogram vid aggressivt B-cellslymfom – fokus på CAR-T, med Professor Mats Jerkeman, Skånes universitetssjukhus i Lund samt Professor Gunilla Enblad, Akademiska sjukhuset i Uppsala. Duration: 12 min Highlights of Transform Study – Breyanzi in R/R LBCL A quick guide to second line treatment and how Breyanzi compares to earlier standard of care in aggressive B-cell lymphoma. Disease Area Specialist Nora Liske gives a short study overview as well as key efficacy and safety outcomes. Duration: cirka 3 min Biomarkers in LBCL Professor Sirpa Leppä, Helsinki University Hospital, share the focus on studying biomarkers to guide physicians in selecting the most appropriate patients for treatment and how to potentially optimize treatment outcomes and minimize the risk of adverse events. Duration: cirka 9 min From Clinical Study To Clinical Practice with CAR-T Professor Stephan Mielke, department of hematology and cell therapy at Karolinska university hospital in Stockholm, shares insights from their CAST team, what patients are appropriate for CAR-T, the journey from participating in clinical trials to clinical practice with CAR-T and how the treatment landscape in 2nd and 3rd line is changing in DLBCL. Interview: 6 minutes How can we improve outcomes for patients with R/R LBCL? Listen to Professor Mats Jerkeman from Skåne University Hospital in Lund, Sweden, as he discusses the treatment gap in R/R LBCL, which patients are suitable for CAR-T, the expected benefits, and the side effect profile associated with CAR-T therapy. Duration: cirka 2 min How to tackle unmet needs in DLBCL? In this interview Professor Sirpa Leppä, Helsinki University Hospital, outlines practical focus areas for the DLBCL working group within the Nordic Lymphoma Group. Listen in to what Prof Leppä shares on high risc populations. Duration: cirka 5 min How to become a CAR-T treatment centra MD Renate Galleberg, Haukeland University Hospital Bergen, gives her view on the motivations to improve patient care in aggressive B-cell lymphoma and her lessions from the path to become a CAR-T treatment centra. Duration: 3 minutes How can we improve outcomes for patients with R/R LBCL? Listen to Prof. Sirpa Leppä, Chair of the Nordic Lymphoma Group, as she discusses key focus areas for improving outcomes across different patient groups with aggressive B-cell lymphomas.
